Alto Neuroscience ANRO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's additional paid-in capital?
- Alto Neuroscience (ANRO) reported additional paid-in capital of $471.22M in Q1 2026.
- How has Alto Neuroscience's additional paid-in capital changed year-over-year?
- Alto Neuroscience's additional paid-in capital increased by 61.0% year-over-year, from $292.64M to $471.22M.
- What is the long-term trend for Alto Neuroscience's additional paid-in capital?
- Over 2 years (2023 to 2025), Alto Neuroscience's additional paid-in capital has grown at a 710.3% compound annual growth rate (CAGR), from $5.37M to $352.75M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.